Bullish indicating open at $55-$60, IPO prices at $37
National Research Corporation (NRC) stock has hit a 52-week low, trading at $11.3, as the company faces a challenging period marked by a significant downturn in its stock value. According to InvestingPro analysis, the stock appears undervalued at current levels, with technical indicators suggesting oversold conditions. Over the past year, NRC has seen its stock price erode, culminating in a steep 1-year change of -66.76%. Despite this decline, the company maintains a P/E ratio of 11.28 and remains profitable, with management actively buying back shares. This dramatic drop reflects investor concerns and a potentially shifting landscape for the company's operations. The 52-week low serves as a critical indicator for shareholders and potential investors, signaling a period of heightened scrutiny and consideration for the company's future financial strategies and market position. For deeper insights into NRC's valuation and growth prospects, including 8 additional ProTips and comprehensive financial analysis, visit InvestingPro.
In other recent news, National Research Corporation has announced changes to its executive compensation structure, aligning more closely with shareholder interests. The adjustments include stock grants and modified cash bonuses for key officers, excluding the CEO roles. Helen L. Hrdy, Chief Operating Officer, will receive 100,000 shares of common stock with specific conditions and a cash bonus tied to the stock's value. Additionally, Andrew Monnich, Chief Corporate Development Officer, will also see changes in his compensation, forfeiting participation in the 2024 long-term cash incentive plan. The board has appointed Trent (NSE:TREN) Green as the incoming CEO, effective June 1, 2025, with the new compensation plan reflecting strategic shifts under his leadership. In another development, NRC Health's Board of Directors approved a quarterly cash dividend of $0.12 per share, payable on April 11, 2025, to shareholders of record as of March 28, 2025. This dividend underscores the company's commitment to returning value to shareholders and confidence in its financial strength. Furthermore, UC Health has partnered with NRC Health to enhance patient care through NRC's Market Insights and Community Insights solutions, aiming to improve business decisions with data-driven strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.